Chronic Kidney Disease in Children
What is the goal of the study?
CKiD Study is a prospective observational longitudinal study in 1,090 children with chronic kidney disease (CKD). The objectives of the CKiD are to determine the risk factors for decline in kidney function; how decline in kidney function impacts risk factors for cardiovascular disease; neurocognitive function and behavior; and growth failure and its associated morbidity. Children enrolled in this study are 6 months to 16 year-old. The subjects’ condition will be evaluated at baseline and 6 months during the first year, then every year for about 15 years. The study will collect medical and family history, clinical exams and labs about kidney function, cardiovascular, with more specialized testing (echo, home blood pressure monitoring, cardiac MRI, neurological assessment, QOL life questionnaires) at various time points. Subjects who undergo renal replacement therapy (RRT) have the option to participate in a yearly follow-up by phone and review of medical records. In a subset of clinical sites, subjects have also the option to participate in a post-RRT substudy where they have two visits at 6 months interval during the first year, followed by yearly visits for up to 5 years. The study includes three cohorts (enrollment is completed for cohorts 1 and 2 and ongoing for cohort 3): • Cohort 1: 600 subjects mild to moderate impaired kidney function (sGFR 30-90 ml/min/1.73 m2) • Cohort 2: 300 subjects with more mildly impaired kidney function with (eGFR 45-90); 150 with glomerular disease and 150 without glomerular disease. • Cohort 3: 190 subjects 6 months to 16 YO with non-glomerular disease and duration of disease of less than 5 years at enrollment to focus on children at early stage of kidney disease. They must have chronic kidney disease but no necessarily impaired kidney function. This cohort will also limit enrollment to 65% of Caucasians to be able to observe disease in non-Caucasians children. The CKiD Study collects serum, plasma, urine, hair, nails and DNA samples during study visits. The data and samples are stored in three repositories: data, biological sample, and a genetic sample repositories. Iohexol GFR testing: Initially used to validate estimating GFR equations. The GFR equations (Schwartz formula and revised versions) are validated except in high values of iGFR. Therefore, test continued in a subset of cohort 1 and 2 when GFR>90 ml/min|1.73m2. The test is optional for Cohort 3.
Who can participate in the study?
Please contact the study team listed below to learn more.